Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 13/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12530535 | 0.92 | EPHX1 (0.51) | EPHX1ACHENAAA | |
| SCHEMBL12530536 | 0.92 | EPHX1 (0.51) | EPHX1ACHENAAA | |
| SCHEMBL12530721 | 0.92 | EPHX1 (0.51) | EPHX1ACHENAAA | |
| SCHEMBL16023972 | 0.92 | EPHX1 (0.51) | EPHX1ACHENAAA | |
| SCHEMBL12530777 | 0.92 | EPHX1 (0.51) | EPHX1ACHENAAA | |
| SCHEMBL16023971 | 0.92 | EPHX1 (0.51) | EPHX1ACHENAAA | |
| Trifluoroacetic Acid SCHEMBL7787315 | 0.90 | EPHX1 (0.42) | EPHX1ACHEFAAH | |
| SCHEMBL6154864 | 0.90 | EPHX1 (0.52) | EPHX1ACHEFAAHCTSK | |
| SCHEMBL16174285 | 0.86 | ACHE (0.46) | EPHX1ACHE | |
| SCHEMBL16174286 | 0.85 | ACHE (0.49) | EPHX1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030097011-A1 | Novel carbamate-based cationic lipids | PROMEGA BIOSCIENCES, INC. (US) | 2003-05-22 | — | — | US | claimed |
| EP-0830368-A1 | NOVEL CARBAMATE-BASED CATIONIC LIPIDS | GENTA INCORPORATED (US) | 1998-03-25 | — | — | EP | claimed |
| WO-1996040726-A9 | NOVEL CARBAMATE-BASED CATIONIC LIPIDS | — | 1997-02-06 | — | — | WO | claimed |
| WO-1996040726-A1 | NOVEL CARBAMATE-BASED CATIONIC LIPIDS | GENTA INCORPORATED (US) | 1996-12-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030097011-A1 | Novel carbamate-based cationic lipids | SGMS1, CETP, PCYT1A | EPHX1 3887/4885ACHE 3039/4885NAAA 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.